RT Journal Article
SR Electronic
A1 Vinall, Phil
T1 AURELIA Analysis Shows Benefits of Bevacizumab as Add-on Therapy in Ovarian Cancer
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 15
SP 8
OP 9
DO 10.1177/155989771215003
UL http://mdc.sagepub.com/content/12/15/8.abstract
AB In patients with ovarian cancer, progression-free survival and overall response rate are significantly improved with the addition of bevacizumab to chemotherapy in front-line [Burger RA et al. N Engl J Med 2011] and platinum-sensitive recurrent [Aghajanian C et al. J Clin Oncol 2012] settings, and as shown in the Phase 3 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer [AURELIA; NCT00976911] trial [Pujade-Lauraine E et al. J Clin Oncol 2012].